Commerce Department Finds Indian Glycine Sold Below Normal Value

Estimated reading time: 2–5 minutes

The United States Department of Commerce has finalized its review regarding the import of glycine from India. The review determined that Indian producers and exporters have been selling glycine in the U.S. at prices below its normal value. This review examined the period from June 1, 2024, to May 31, 2025.

Key Findings

  • The final results confirm the preliminary findings issued earlier this year. The preliminary results had found that some Indian companies were selling glycine at unfairly low prices.
  • The companies Medilane Healthcare Private Limited and Mulji Mehta Enterprises were found to have dumping margins of 57.17%.

Implications

  • The Department of Commerce will instruct U.S. Customs and Border Protection to assess antidumping duties on these imports.
  • The cash deposit rate for Medilane Healthcare Private Limited and Mulji Mehta Enterprises will be set at 57.17%.

Additional Details

  • Cash deposit rates for other companies will depend on whether they were part of this review or a previous one. If a company was not reviewed, rates from the most recent segment will apply.
  • If neither the exporter nor the producer has previously been reviewed, a standard rate of 7.23% will apply.

Responsibilities for Importers

  • Importers must file a certificate concerning the reimbursement of any antidumping or countervailing duties before their entries are liquidated. If they fail to do so, they could face double duties or increased duties.

Privacy and Compliance

  • Parties involved should respect agreements regarding proprietary information as laid out by the Department of Commerce.

These results have been issued according to U.S. law and will be enforced to ensure fair trade practices.


Legal Disclaimer

This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.